TP53 and acute myeloid leukemia: Younger, adverse-risk AML patients, including those with complex karyotypes or TP53-mutations achieved, however, higher rates of response with 5 days of DEC + VEN compared to AZA + VEN based on the results of the phase 2 NCT04752527 [16].